5.5. biopsy strategy. prostate biopsy performed using different strategies (systematic, targeted etc) approaches (i.e. transperineal vs. transrectal). 5.5.1. systematic biopsy strategy systematic biopsies, prior imaging used targeting, sample sites bilateral apex base, far posterior lateral possible peripheral gland regardless approach used. 2006 sr showed twelve minimum number cores systematic biopsies, > twelve cores increasing cancer detection rate significantly . 5.5.2. targeted biopsy strategy mri shown suspicious lesion, mr-targeted biopsy obtained cognitive guidance, us/mr fusion software direct in-bore guidance. current literature, including srs meta-analyses, show clear superiority one image-guided technique another [308-310]. target biopsy techniques based magnetic resonance imaging diagnosis prostate cancer patients prior negative biopsies (future) randomised trial compared three techniques (cognitive fusion, software fusion, in-bore mri) mri-targeted biopsy repeat-biopsy setting found differences cancer detection . 5.5.3. targeted biopsy versus systematic biopsy 5.5.3.1. increased detection cancers labelled clinically significant precision (prostate evaluation clinically important disease: sampling using image guidance not?) precise (prostate evaluation clinically important disease: mri vs. standard evaluation procedures) prospective trials randomized biopsy naïve patients either ten twelve core systematic biopsy mri subsequent mri-targeted biopsy (up four cores) case positive mri. found mri-targeted biopsy significantly out-performed inferior systematic biopsy detection isup grade group ≥ 2 cancers. pooled data 25 reports agreement analysis (head-to-head comparisons) systematic biopsy (median number cores: 8–15) mri-targeted biopsies (median number cores: 2–7), detection ratio (i.e. ratio detection rates obtained mri-targeted biopsy alone systematic biopsy alone) 1.12 (95% ci: 1.02–1.23) isup grade group ≥ 2 cancers 1.20 (95% ci: 1.06–1.36) isup grade group ≥ 3 cancers, therefore favour mri-targeted biopsy . another meta-analysis studies limited biopsy-naive patients positive mri also found mri-targeted biopsy detected significantly isup grade group ≥ 2 cancers systematic biopsy (risk difference, -0.11 [95% ci: -0.2 0.0]; p = 0.05) . data confirmed prospective multi-centre trials evaluated mri-targeted biopsy biopsy-naive patients . subgroup 152 patients future trial underwent mri-targeted biopsy systematic biopsy repeat biopsy setting, mri-targeted biopsy detected significantly isup grade group ≥ 2 cancers systematic biopsy (34% vs. 16%; p < 0.001, detection ratio 2.1) . findings support mri-targeted biopsy significantly out-performs systematic biopsy detection isup grade ≥ 2 also repeat-biopsy setting. 5.5.3.2. reduced detection cancers labelled isup grade group 1 pooled data 25 head-to-head comparisons systematic biopsy mri-targeted biopsy, detection ratio isup grade group 1 cancers 0.62 (95% ci: 0.44–0.88) patients prior negative biopsy 0.63 (95% ci: 0.54–0.74) biopsy-naive patients . precision 4m trials, detection rate isup grade group 1 patients significantly lower mri-targeted biopsy group compared systematic biopsy (9% vs. 22%, p < 0.001, detection ratio 0.41 precision; 14% vs. 25%, p < 0.001, detection ratio 0.56 4m) . mri-first trial, mri-targeted biopsy detected significantly fewer patients clinically insignificant pca (defined isup grade group 1 maximum cancer core length < 6 mm) systematic biopsy (5.6% vs. 19.5%, p < 0.0001, detection ratio 0.29) . consequently, mri-targeted biopsy without systematic biopsy significantly reduces over-diagnosis low-risk disease, compared systematic biopsy. seems true even systematic biopsies indicated risk stratification rotterdam prostate cancer risk calculator) . 5.5.3.3. added value systematic biopsy targeted biopsy head-to-head comparisons two biopsy techniques, possible compute added value, i.e. percentage additional patients cspca contribute diagnose. table 5.3 shows added value systematic mri-targeted biopsy isup grade group ≥ 2 ≥ 3 cancer detection. absolute added values table refer percentage patients entire cohort; cancer prevalence considered, ‘relative’ percentage additional detected cspca computed. adding mri-targeted biopsy systematic biopsy biopsy-naive patients increases number detected isup grade ≥ 2 grade ≥ 3 pca approximately 20% 30%, respectively. repeat-biopsy setting, adding mri-targeted biopsy increases detection isup grade group ≥ 2 grade group ≥ 3 pca approximately 40% 50%, respectively. omitting systematic biopsy biopsy-naive patients would miss approximately 16% detected isup grade group ≥ 2 pca 18% isup grade ≥ 3 pca. repeat-biopsy setting, would miss approximately 10% isup grade group ≥ 2 pca 9% isup grade group ≥ 3 pca. low added value systematic biopsy repeat biopsy setting confirmed studies reported absolute added values 1.2-3.9% detection isup grade group ≥2 cancers 1.2-1.6% isup grade group ≥ 3 cancers . table 5.5: absolute added values targeted systematic biopsies isup grade ≥ 2 ≥ 3 cancer detection isup > 2isup > 3isup gradecochrane meta-analysis* mri-first trial* 4m trial cochrane meta-analysis* mri-first trial* 4m trial biopsy-naïveadded value mri-tbx6.3%(4.8–8.2)7.6%(4.6–11.6)7.0% (nd)4.7%(3.5–6.3)6.0%(3.4–9.7)3.2% (nd)added value systematic biopsy4.3%(2.6–6.9)5.2%(2.8–8.7)5.0% (nd)2.8%(1.7–4.8)1.2%(0.2–3.5)4.1% (nd)overall prevalence27.7% (23.7–32.6)37.5% (31.4–43.8)30% (nd)15.5% (12.6–19.5)21.1% (16.2–26.7)15% (nd)prior negative biopsyadded value mri-tbx9.6%(7.7–11.8)--6.3%(5.2–7.7)--added value ofsystematic biopsy2.3%(1.2–4.5)--1.1%(0.5–2.6)--overall prevalence22.8% (20.0–26.2)--12.6% (10.5–15.6)-- *intervals parenthesis 95% ci.the absolute added value given biopsy technique defined percentage patients entire cohort diagnosed biopsy technique.isup = international society urological pathology (grade); mri-tbx = magnetic resonance imaging-targeted biopsies; nd = defined. table 5.6: detection rates isup grade group 1 cancers targeted systematic biopsies studytargeted biopsysystematic biopsyp-valueprecision 9%22%<0.001precise 10.121.7<0.001mri-first *5.6%19.5%<0.00014m 14%24.7%<0.0001cochrane meta-analysis 13.5%22.4%<0.01 * mri-first trial, percentages refer detection rates isup 1 cancers maximum cancer core length < 6 mm 5.5.4. perilesional biopsy minimum three five cores required proper sampling mri detected lesion . including additional peri-lesional/regional systematic biopsies, rather standard sextant-based systematic biopsies may decrease total number cores taken (by avoiding systematic biopsies mri-negative lobes) improve detection cspca (by compensating guiding imprecision). addition, mri-targeted regional biopsy approach could avoid detecting 12-17% insignificant cancers detected classical combined approach [315-317]. meta-analysis eight studies showed non-significant difference detection isup grade group ≥2 cancer mri-directed targeted regional biopsy approach, compared recommended practice mri-directed targeted- systematic biopsy approach (rr: 0.95, 95% ci: 0.90–1.01; p = 0.09). however, mri-directed targeted- regional biopsy approach detected significantly isup grade group ≥2 cancers mri-targeted biopsy alone (rr: 1.18, 95% ci: 1.10–1.25; p < 0.001) . prospective retrospective studies included meta-analysis provided similar evidence(table 5.7). two studies retrospectively used location biopsy cores registered mri/us fusion systems assess added value systematic cores based distance nearest mri lesion. diagnostic yield systematic cores decreased increasing distance. combining targeted systematic cores located within 10 mm 15 mm radius mr lesions detected 90-92% 94-97% cspca respectively . width distance mri lesion enclosed 90% cspca may also depend pi-rads score lesion; one series found 5.5 mm, 12 mm 16 mm lesions pi-rads scores 5, 4 3 respectively . consequence, men pi-rads 5 index lesion, absolute added value additional biopsy repeatedly found less 4% isup grade group ≥ 2 cancers less 2% isup grade group ≥ 3 cancers [313,320-322]. 5.5.5. prostate mri mri-targeted biopsy reproducibility despite use pi-rads scoring systems, mri inter-reader reproducibility remains moderate best. mri performance better experienced radiologists high-volume centres. currently limits broad use non-dedicated radiologists . accuracy mri-targeted biopsy also substantially impacted experience biopsy operator . precise trial, reproduced design precision trial obtained quite different results. trials, detection rate isup grade group ≥2 pca higher mri pathway classical systematic biopsy pathway. yet, difference much lower precise trial (+5.2% vs. +12.1% isup grade group ≥2 cancers; +2.1% vs. +5.5% isup grade group ≥3 cancers). addition, major intersite variability precise trial: centre highest cspca detection rate mri-targeted biopsy lowest systematic biopsy vice versa. factors variability give rise concerns reproducibility good results mri-directed diagnostic pathways. efforts towards standardization whole diagnostic pathway (mri acquisition interpretation, biopsy planning acquisition) quality assurance quality control currently undertaken . however, significant improvement accuracy mri mri-targeted biopsy observed time simple measures training participation mdt meeting pathological correlation feedback . whether artificial intelligence-based assistance improve mri interpretation accuracy remains questionable, preliminary studies reported conflicting results topic . 5.5.6. cancer grade shift mri findings significant predictors adverse pathology features prostatectomy specimens, survival-free bcr rp rt . addition, tumours visible mri enriched molecular hallmarks aggressivity, compared invisible lesions . thus, mri identify aggressive tumours. nonetheless, mri-targeted biopsy sensitive systematic biopsy detecting areas high-grade cancer, isup grade group ≥ 2 cancers detected mri-targeted biopsy are, average, better prognosis detected classical diagnostic pathway (will rogers phenomenon . illustrated retrospective series 1,345 patients treated rp showed that, risk groups, patients diagnosed mri-targeted biopsy better bcr-free survival diagnosed systematic biopsy . mitigate grade shift, case targeted biopsies, 2019 isup consensus conference recommended using aggregated isup grade group summarizing results biopsy cores mr lesion, rather using result core highest isup grade group (see pathology section 4.2). long term follow-up patients underwent mri-targeted biopsy available, revision risk-groups definition become necessary. meantime, results mri-targeted biopsy must interpreted context potential grade shift . table 5.7: detection rates isup grade group ≥2 prostate cancer achieved targeted biopsy, combined systematic targeted biopsy targeted biopsy perilesional sampling type studynb ptstargeted biopsy perilesional samplingvs.combined systematic targeted biopsytargeted biopsy perilesional samplingvs.targeted biopsyratio detection ratesmedian number coresratio detection ratesmedian number coreshagens mj meta-analysis26030.95 (0.90 – 1.01), p=0.099.5 [7.5-12.3] vs. 16.5 [15.3 – 12.3]1.18 (1.1 – 1.25), p<0.0019.5 [7.5 – 12.3] vs. 3.5 [3 – 4]hagens mj retrospective, single centre2350.968 (0.91 – 0.993)7 [6 – 9] vs. 12 [10 – 15]--hsieh pf, j 18:127 prospective, single centre100115 [12.8 – 18] vs. 26 [23 – 28]1.20, p=0.00815 [12.8 – 18] vs. 6 [4 – 7] 5.5.7. guidelines mri imaging biopsy indication strategy recommendationsstrength ratingdo use magnetic resonance imaging (mri) initial screening tool.strongadhere pi-rads guidelines mri acquisition interpretation evaluate mri results multidisciplinary meetings pathological feedback.strongwhere mri shown suspicious lesion, mr-targeted biopsy obtained cognitive guidance, us/mr fusion software direct in-bore guidance.weakperform mri prostate biopsy men suspected organ confined disease.strongin men suspicion locally advanced disease digital rectal examination (dre) and/or prostate-specific antigen (psa)>50 ng/ml, curative treatments, consider limited biopsy without mri.weakwhen mri positive (i.e. pi-rads ≥ 4), combine targeted biopsy perilesional sampling.weakwhen mri negative (i.e., pi-rads ≤ 2), clinical suspicion pca low (psa density < 0.20 ng/ml/cc, negative dre findings, family history), omit biopsy offer psa monitoring; otherwise consider systematic biopsy.weakwhen mri indeterminate (pi-rads = 3), clinical suspicion pca low (psa density < 0.10 ng/ml/cc, negative dre findings, family history), omit biopsy offer psa monitoring; otherwise consider targeted biopsy perilesional sampling.weakif mri available, use risk calculator systematic biopsies indicated.strongwhen performing systematic biopsy only, least twelve cores recommended.strong